With reference to the agreement signed on 19/04/2017 with the Greek company DEMO SA and the start of sales of Deferoxamine Noridem 2 g on 30/05/2017, C.F.I. SRL has also launched Deferoxamine Noridem 500 mg in the Italian market. Deferoxamine mesylate is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias.